logo

For the Inventor, By the Inventor

South San Francisco, CA, United States of America

Threshold Pharmaceuticals, Inc.

Calculating rank
USPTO Granted Patents = 19

% Expired Patents = 42.1



Trademarks = 2

Forward Citations = 203

Loading Chart...
Loading Chart...

19 inventors (with patents filed for the assignee):

goldMedal Mark D Matteucci (12 out of 65 patents)

silverMedal Jian-Xin Duan (10 out of 18 patents)

bronzeMedal George Tidmarsh (7 out of 17 patents)

4.  Hailong Jiao (6 out of 12 patents)

5.  Photon Rao (3 out of 4 patents)

6.  Charles Praray Hart (2 out of 5 patents)

7.  Stewart Kroll (2 out of 3 patents)

8.  Jacob Kaizerman (2 out of 2 patents)

9.  Tao Chen (1 out of 240 patents)

10.  Yeyu Cao (1 out of 7 patents)

11.  Xiaohong Cai (1 out of 7 patents)

12.  Fanying Meng (1 out of 1 patent)

13.  Jessica Sun (1 out of 1 patent)

14.  John G Curd (1 out of 1 patent)

15.  Damian Handisides (1 out of 1 patent)


19 patents:

1. 9254299 - Administration of hypoxia activated prodrugs in combination with Chk1 inhibitors for treating cancer (2016-02-09),
2. 9226932 - Phosphoramidate alkylator prodrugs (2016-01-05),
3. 9205098 - Anti-cancer therapies (2015-12-08),
4. 8946275 - Treatment of cancer using hypoxia activated prodrugs (2015-02-03),
5. 8765690 - Treatment of cancer with glufosfamide in patients not receiving insulin therapy (2014-07-01),
6. 8664204 - Phosphoramidate alkylator prodrugs (2014-03-04),
7. 8575188 - Camptothecin derivatives (2013-11-05),
8. 8552048 - Phosphoramidate alkylator prodrugs for the treatment of cancer (2013-10-08),
9. 8507464 - Phosphoramidate alkylator prodrugs (2013-08-13),
10. 8318683 - Anti-cancer therapies (2012-11-27),
11. 8309554 - Hypoxia activated drugs of nitrogen mustard alkylators (2012-11-13),
12. 8299088 - Compositions and methods for treating cancer (2012-10-30),
13. 8003625 - Phosphoramidate alkylator prodrugs (2011-08-23),
14. 7560230 - Method for determining susceptibility of tumor to treatment with anti-neoplastic agent (2009-07-14),
15. 7550496 - Compositions and methods for treating cancer (2009-06-23),
Company Overview
Threshold Pharmaceuticals, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on developing innovative therapies for cancer treatment. The company specializes in the discovery and commercialization of novel compounds that target the unique metabolic pathways of tumors, aiming to improve patient outcomes. Through its research, Threshold seeks to address unmet medical needs in oncology, leveraging advanced scientific insights to create effective therapeutic options.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

19 Patents

#68 in South San Francisco, CA

#4,108 in California

#17,154 in US

#32,705 in the World

South San Francisco, CA (US)
South San Francisco, CA, United States of America

Threshold Pharmaceuticals, Inc.

Forward Citations = 203

19 inventors:

goldMedal Mark D Matteucci (12 out of 65 patents)

silverMedal Jian-Xin Duan (10 out of 18 patents)

bronzeMedal George Tidmarsh (7 out of 17 patents)

4.  Hailong Jiao (6 out of 12 patents)

5.  Photon Rao (3 out of 4 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Threshold Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/threshold-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…